Aerie Pharmaceuticals Inc logo

AERI - Aerie Pharmaceuticals Inc Share Price

$12.89 0.3  2.2%

Last Trade - 10/08/20

Sector
Healthcare
Size
Mid Cap
Market Cap £449.0m
Enterprise Value £394.7m
Revenue £60.8m
Position in Universe 2829th / 6393
Bullish
Bearish
Unlock AERI Revenue
Momentum
Relative Strength (%)
1m -11.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -52.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 24.2 69.9 82.5 132
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Aerie Pharmaceuticals Inc revenues increased 87% to $20.3M. Net loss increased 2% to $49.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase from $798K to $6.4M (expense), General and administrative -Other increase of 10% to $30M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AERI Revenue Unlock AERI Revenue

Net Income

AERI Net Income Unlock AERI Revenue

Normalised EPS

AERI Normalised EPS Unlock AERI Revenue

PE Ratio Range

AERI PE Ratio Range Unlock AERI Revenue

Dividend Yield Range

AERI Dividend Yield Range Unlock AERI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AERI EPS Forecasts Unlock AERI Revenue
Profile Summary

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated June 22, 2005
Public Since October 25, 2013
No. of Shareholders: 253
No. of Employees: 380
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 46,468,255
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AERI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AERI
Upcoming Events for AERI
Frequently Asked Questions for Aerie Pharmaceuticals Inc
What is the Aerie Pharmaceuticals Inc share price?

As of 10/08/20, shares in Aerie Pharmaceuticals Inc are trading at $12.89, giving the company a market capitalisation of £449.0m. This share price information is delayed by 15 minutes.

How has the Aerie Pharmaceuticals Inc share price performed this year?

Shares in Aerie Pharmaceuticals Inc are currently trading at $12.89 and the price has moved by -44.98% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aerie Pharmaceuticals Inc price has moved by -52.05% over the past year.

What are the analyst and broker recommendations for Aerie Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Aerie Pharmaceuticals Inc, there are there are currently 3 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aerie Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aerie Pharmaceuticals Inc next release its financial results?

Aerie Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Aerie Pharmaceuticals Inc dividend yield?

Aerie Pharmaceuticals Inc does not currently pay a dividend.

Does Aerie Pharmaceuticals Inc pay a dividend?

Aerie Pharmaceuticals Inc does not currently pay a dividend.

When does Aerie Pharmaceuticals Inc next pay dividends?

Aerie Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Aerie Pharmaceuticals Inc shares?

To buy shares in Aerie Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aerie Pharmaceuticals Inc?

Shares in Aerie Pharmaceuticals Inc are currently trading at $12.89, giving the company a market capitalisation of £449.0m.

Where are Aerie Pharmaceuticals Inc shares listed? Where are Aerie Pharmaceuticals Inc shares listed?

Here are the trading details for Aerie Pharmaceuticals Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: AERI
What kind of share is Aerie Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Aerie Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aerie Pharmaceuticals Inc share price forecast 2020?

Shares in Aerie Pharmaceuticals Inc are currently priced at $12.89. At that level they are trading at 0.136% discount to the analyst consensus target price of 0.00.

Analysts covering Aerie Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.209 for the next financial year.

How can I tell whether the Aerie Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aerie Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -38.4%. At the current price of $12.89, shares in Aerie Pharmaceuticals Inc are trading at -27.28% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aerie Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Aerie Pharmaceuticals Inc.

Who are the key directors of Aerie Pharmaceuticals Inc?

Aerie Pharmaceuticals Inc's management team is headed by:

Casey Kopczynski - CFD
Richard Rubino - CFO
David Gryska - LED
Vicente Anido - CHM
Gerald Cagle - IND
Murray Goldberg - IND
Thomas Mitro - PRE
Benjamin McGraw - LED
Richard Croarkin - IND
Mechiel Du Toit - IND
Eric Carlson - VRD
John LaRocca - GCN
Amine Sinmazisik - FID
Christopher Staten - VFN
Michelle Senchyna - VPR
Nina Ohara - DMK
David Hollander - OTH
Peter McDonnell - DRC
Who are the major shareholders of Aerie Pharmaceuticals Inc?

Here are the top five shareholders of Aerie Pharmaceuticals Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.35% (4.34m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.73% (3.13m shares)
Partner Fund Management, L.L.C. Hedge Fund
Percentage owned: 5.44% (2.53m shares)
Levin Capital Strategies, L.P. Investment Advisor/Hedge Fund
Percentage owned: 3.23% (1.50m shares)
Fred Alger Management, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.01% (1.40m shares)
Similar to AERI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.